PLA2R1 and kidney disorder: PLA2R is the primary target antigen of IMN (70%–80%), and a PLA2R antibody titer greater than 50RU/mL is defined as a high risk for IMN according to the Kidney Disease Improving Global Outcomes (KDIGO) 2021 guideline.